Oligometastatic Cancer: Key Concepts and Research Opportunities for 2021 and Beyond

doi:10.3390/cancers13112518

Editorial

. 2021 May 21;13(11):2518.

doi: 10.3390/cancers13112518.

Oligometastatic Cancer: Key Concepts and Research Opportunities for 2021 and Beyond

Petr Szturz¹, Jan B Vermorken^{2

3}

Affiliations

¹ Medical Oncology, Department of Oncology, Lausanne University Hospital (CHUV), 1011 Lausanne, Switzerland.
² Department of Medical Oncology, Antwerp University Hospital, 2650 Edegem, Belgium.
³ Faculty of Medicine and Health Sciences, University of Antwerp, 2610 Antwerp, Belgium.

PMID: 34063904
PMCID: PMC8196648
DOI: 10.3390/cancers13112518

Editorial

Oligometastatic Cancer: Key Concepts and Research Opportunities for 2021 and Beyond

Petr Szturz et al. Cancers (Basel). 2021.

. 2021 May 21;13(11):2518.

doi: 10.3390/cancers13112518.

Authors

Petr Szturz¹, Jan B Vermorken^{2

3}

Affiliations

¹ Medical Oncology, Department of Oncology, Lausanne University Hospital (CHUV), 1011 Lausanne, Switzerland.
² Department of Medical Oncology, Antwerp University Hospital, 2650 Edegem, Belgium.
³ Faculty of Medicine and Health Sciences, University of Antwerp, 2610 Antwerp, Belgium.

PMID: 34063904
PMCID: PMC8196648
DOI: 10.3390/cancers13112518

Abstract

Traditionally, clinicians distinguished three forms of cancer outgrowth [...].

PubMed Disclaimer

Conflict of interest statement

P.S.: has had in the last three years or has advisory relationships with: Merck-Serono, Servier, and BMS. J.B.V.: has had in the last three years or has consulting/advisory relationships with: Immunomedics, Innate Pharma, Merck-Serono, Merck Sharp & Dome Corp, PCI Biotech, Synthon Biopharmaceuticals, Debiopharm, Cue Biopharma, and WntResearch and received lecture fees from Merck-Serono, MSD, and BMS.

Figures

**Figure 1**
Development of clinically overt malignant disease with a possibility of oligometastatic cancer, as an intermediate state between locoregionally advanced and typical metastatic disease, and its different forms.

**Figure 2**
Increasing number of scientific papers on oligometastatic disease per year from 1996 to 2020. Results correspond to the search term “oligometastatic” in the National Library of Medicine on 4 April 2021 (https://pubmed.ncbi.nlm.nih.gov).

See this image and copyright information in PMC

Cited by

Oligometastatic Non-Small Cell Lung Cancer: A Practical Review of Prospective Trials.
Baydoun A, Lee VL, Biswas T. Baydoun A, et al. Cancers (Basel). 2022 Oct 29;14(21):5339. doi: 10.3390/cancers14215339. Cancers (Basel). 2022. PMID: 36358757 Free PMC article. Review.
Essential updates 2021/2022: Surgical outcomes of oligometastasis in pancreatic ductal adenocarcinoma.
Yasuda S, Nagai M, Terai T, Kohara Y, Sho M. Yasuda S, et al. Ann Gastroenterol Surg. 2023 Jan 18;7(3):358-366. doi: 10.1002/ags3.12655. eCollection 2023 May. Ann Gastroenterol Surg. 2023. PMID: 37152775 Free PMC article. Review.
Stereotactic Body Radiation Therapy in Patients with Oligometastatic Disease: Clinical State of the Art and Perspectives.
Kinj R, Muggeo E, Schiappacasse L, Bourhis J, Herrera FG. Kinj R, et al. Cancers (Basel). 2022 Feb 23;14(5):1152. doi: 10.3390/cancers14051152. Cancers (Basel). 2022. PMID: 35267460 Free PMC article. Review.
Imaging of Oligometastatic Disease.
Vietti Violi N, Hajri R, Haefliger L, Nicod-Lalonde M, Villard N, Dromain C. Vietti Violi N, et al. Cancers (Basel). 2022 Mar 10;14(6):1427. doi: 10.3390/cancers14061427. Cancers (Basel). 2022. PMID: 35326586 Free PMC article. Review.

References

1. Amin M.B., Edge S., Greene F., Byrd D.R., Brookland R.K., Washington M.K., Gershenwald J.E., Compton C.C., Hess K.R., Sullivan D.C., et al., editors. AJCC Cancer Staging Manual. 8th ed. Springer International Publishing; Cham, Switzerland: 2017.
1. Lievens Y., Guckenberger M., Gomez D., Hoyer M., Iyengar P., Kindts I., Méndez Romero A., Nevens D., Palma D., Park C., et al. Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. Radiother. Oncol. 2020;148:157–166. doi: 10.1016/j.radonc.2020.04.003. - DOI - PubMed
1. Guckenberger M., Lievens Y., Bouma A.B., Collette L., Dekker A., deSouza N.M., Dingemans A.C., Fournier B., Hurkmans C., Lecouvet F.E., et al. Characterisation and classification of oligometastatic disease: A European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020;21:e18–e28. doi: 10.1016/S1470-2045(19)30718-1. - DOI - PubMed
1. Gutiontov S.I., Pitroda S.P., Weichselbaum R.R. Oligometastasis: Past, Present, Future. Int. J. Radiat. Oncol. Biol. Phys. 2020;108:530–538. doi: 10.1016/j.ijrobp.2020.02.019. - DOI - PubMed
1. Szturz P., Nevens D., Vermorken J.B. Oligometastatic Disease Management: Finding the Sweet Spot. Front. Oncol. 2020;10:617793. doi: 10.3389/fonc.2020.617793. - DOI - PMC - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources

[1] Amin M.B., Edge S., Greene F., Byrd D.R., Brookland R.K., Washington M.K., Gershenwald J.E., Compton C.C., Hess K.R., Sullivan D.C., et al., editors. AJCC Cancer Staging Manual. 8th ed. Springer International Publishing; Cham, Switzerland: 2017.

[2] Amin M.B., Edge S., Greene F., Byrd D.R., Brookland R.K., Washington M.K., Gershenwald J.E., Compton C.C., Hess K.R., Sullivan D.C., et al., editors. AJCC Cancer Staging Manual. 8th ed. Springer International Publishing; Cham, Switzerland: 2017.

[3] Lievens Y., Guckenberger M., Gomez D., Hoyer M., Iyengar P., Kindts I., Méndez Romero A., Nevens D., Palma D., Park C., et al. Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. Radiother. Oncol. 2020;148:157–166. doi: 10.1016/j.radonc.2020.04.003. - DOI - PubMed

[4] Lievens Y., Guckenberger M., Gomez D., Hoyer M., Iyengar P., Kindts I., Méndez Romero A., Nevens D., Palma D., Park C., et al. Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. Radiother. Oncol. 2020;148:157–166. doi: 10.1016/j.radonc.2020.04.003. - DOI - PubMed

[5] Guckenberger M., Lievens Y., Bouma A.B., Collette L., Dekker A., deSouza N.M., Dingemans A.C., Fournier B., Hurkmans C., Lecouvet F.E., et al. Characterisation and classification of oligometastatic disease: A European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020;21:e18–e28. doi: 10.1016/S1470-2045(19)30718-1. - DOI - PubMed

[6] Guckenberger M., Lievens Y., Bouma A.B., Collette L., Dekker A., deSouza N.M., Dingemans A.C., Fournier B., Hurkmans C., Lecouvet F.E., et al. Characterisation and classification of oligometastatic disease: A European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020;21:e18–e28. doi: 10.1016/S1470-2045(19)30718-1. - DOI - PubMed

[7] Gutiontov S.I., Pitroda S.P., Weichselbaum R.R. Oligometastasis: Past, Present, Future. Int. J. Radiat. Oncol. Biol. Phys. 2020;108:530–538. doi: 10.1016/j.ijrobp.2020.02.019. - DOI - PubMed

[8] Gutiontov S.I., Pitroda S.P., Weichselbaum R.R. Oligometastasis: Past, Present, Future. Int. J. Radiat. Oncol. Biol. Phys. 2020;108:530–538. doi: 10.1016/j.ijrobp.2020.02.019. - DOI - PubMed

[9] Szturz P., Nevens D., Vermorken J.B. Oligometastatic Disease Management: Finding the Sweet Spot. Front. Oncol. 2020;10:617793. doi: 10.3389/fonc.2020.617793. - DOI - PMC - PubMed

[10] Szturz P., Nevens D., Vermorken J.B. Oligometastatic Disease Management: Finding the Sweet Spot. Front. Oncol. 2020;10:617793. doi: 10.3389/fonc.2020.617793. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Oligometastatic Cancer: Key Concepts and Research Opportunities for 2021 and Beyond

Affiliations

Oligometastatic Cancer: Key Concepts and Research Opportunities for 2021 and Beyond

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources